Department of Physical Medicine and Rehabilitation, Haddasah-Hebrew University Hospital, Jerusalem, Israel.
Mult Scler. 2012 Jun;18(6):881-90. doi: 10.1177/1352458511431075. Epub 2011 Dec 6.
Preservation of locomotor activity in multiple sclerosis (MS) patients is of utmost importance. Robotic-assisted body weight-supported treadmill training is a promising method to improve gait functions in neurologically impaired patients, although its effectiveness in MS patients is still unknown.
To compare the effectiveness of robot-assisted gait training (RAGT) with that of conventional walking treatment (CWT) on gait and generalized functions in a group of stable MS patients.
A prospective randomized controlled trial of 12 sessions of RAGT or CWT in MS patients of EDSS score 5-7. Primary outcome measures were gait parameters and the secondary outcomes were functional and quality of life parameters. All tests were performed at baseline, 3 and 6 months post-treatment by a blinded rater.
Fifteen and 17 patients were randomly allocated to RAGT and CWT, respectively. Both groups were comparable at baseline in all parameters. As compared with baseline, although some gait parameters improved significantly following the treatment at each time point there was no difference between the groups. Both FIM and EDSS scores improved significantly post-treatment with no difference between the groups. At 6 months, most gait and functional parameters had returned to baseline.
Robot-assisted gait training is feasible and safe and may be an effective additional therapeutic option in MS patients with severe walking disabilities.
多发性硬化症(MS)患者保持运动能力至关重要。机器人辅助的体重支撑跑步机训练是一种改善神经功能障碍患者步态功能的有前途的方法,尽管其在 MS 患者中的有效性仍不清楚。
比较机器人辅助步态训练(RAGT)与传统步行治疗(CWT)对一组稳定 MS 患者步态和全身功能的疗效。
一项前瞻性随机对照试验,对 EDSS 评分 5-7 的 MS 患者进行 12 次 RAGT 或 CWT。主要结局指标为步态参数,次要结局指标为功能和生活质量参数。所有测试均由盲法评估者在基线、治疗后 3 个月和 6 个月进行。
15 名和 17 名患者分别随机分配到 RAGT 和 CWT 组。两组在所有参数上均具有可比性。与基线相比,尽管在每个时间点治疗后某些步态参数均显著改善,但两组之间没有差异。FIM 和 EDSS 评分在治疗后均显著改善,两组之间无差异。6 个月时,大多数步态和功能参数已恢复到基线。
机器人辅助步态训练是可行且安全的,可能是严重步行障碍的 MS 患者的有效附加治疗选择。